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Alzheimer’s disease(AD) and Parkinson's disease (PD) are the two most common progressive 
central neurodegenerative diseases affecting the population over the age of 60 years. Apart from 
treatments that temporarily improve symptoms, there is no medicine currently available which 
can inhibit or reverse the progression of AD and PD. In Traditional Chinese Medicine (TCM), the 
root of Scutellaria baicalensis Georgi is a classic compatible component in decoction of herbal 
medicine used for treating central nervous system (CNS) diseases. Modern pharmacokinetic 
studies have confirmed that baicalein (5, 6, 7-trihydroxyflavone) is a major bioactive flavone 
constituent root of of Scutellaria baicalensis Georgi. Studies showed that baicalein possesses a 
range of key pharmacological properties, such as reducing oxidative stress, anti-inflammatory 
properties, inhibiting aggregation of disease-specific amyloid proteins, inhibiting excitotoxicity, 
stimulating neurogenesis and differentiation action, and anti-apoptosis effect. Based on these, 
baicalein shows therapeutic potential for AD and PD. In the present review, we will summarize 
the pharmacological protective actions of baicalein that make it suitable for the treatment of AD 
and PD, and the potential mechanisms underlying the effects will also be discussed. 
 
Key points: 
1. No cures are available for inhibiting or reversing the progression of Alzheimer’s disease (AD) 
and Parkinson's disease (PD).  
2. Active ingredients of traditional Chinese medicine (TCM) show good therapeutic effects on 
age-related central nervous system (CNS) diseases. 
3. Baicalein, a major bioactive flavone constituent of Scutellaria baicalensis Georgi, has been in 




Alzheimer’s disease (AD) and Parkinson's disease (PD) are the most common two progressive 
central neurodegenerative diseases affecting the population over the age of 60 years. 
Pathologically, AD is characterized by extracellular β-amyloid (Aβ) plaques and intracellular 
neurofibrillary tangles in the brain. AD manifests itself in progressive memory loss and cognitive 
decline, accompanied with changes in emotion and even psychiatric symptoms (Cavallucci et al., 
2012). The pathology of PD is characterized by a progressive loss of dopaminergic neurons and 
nerve fibers in the nigrostriatal system which leads to tremors, muscular rigidity, bradykinesia, 
and postural and gait abnormalities (Kowal et al., 2013). With the increasing aging population, 
the incidence of AD and PD is on the rise and is becoming a large economic burden to society and 
to patient families (Reitz et al., 2011). However, no cures are available for these central 
neurodegenerative diseases.   
 
Currently, the main approach to the treatment of AD is trying to augment cholinergic 
neurotransmission in the brain. This involves the use of cholinesterase inhibitors such as tacrine, 
galantamine, rivastigmine, and donepezil (Kulshreshtha and Piplani, 2016). In PD, administering 
the dopamine precursor L-dopa remains the standard treatment for the symptoms of PD in the 
last 30 years (Olanow and Schapira, 2013). However, these medicines can only improve the 
symptoms temporarily; they cannot inhibit or reverse the progression of AD and PD. The 
long-term use of them produces various adverse effects and complications, and eventually fails to 
improve symptoms of patients any longer as the disease progresses (Kumar et al., 2015; Sharma 
et al., 2015). Therefore, there is a great need for the development of new 
anti-neurodegeneration drugs that can stop disease progression.     
 
In oriental countries, a variety of traditional Chinese medicine (TCM) preparations contain 
different kinds of herbal medicines which have proven to have good therapeutic effects on 
age-related central nervous system (CNS) diseases, including dementia, cerebral stroke and 
paralysis, in clinical practice for centuries (Li et al., 2013b; More et al., 2013). However, the 
molecular mechanisms involved in TCM remain unclear; they are therefore not readily accepted 
by practitioners of modern Western medicine. The systematic identification of these mechanisms 
with modern pharmacological and biochemical techniques can be challenging (Wang et al., 
2016b). Interestingly, the root of Scutellaria baicalensis Georgi is a classic compatible component 
in decoction of herbal medicine used for treating CNS diseases, and there are reports that 
elevated consumption of dietary supplements containing the herbal medicine is associated with a 
lower incidence of dementia and other age-related neurological disorders (Gasiorowski et al., 
2011). Nevertheless, more research is required to uncover its molecular actions.   
  
Scutellaria baicalensis Georgi (Chinese herbal name: Huang qin) is extensively cultivated in China, 
Siberia, Mongolia, the Russian Far East, Korea and Japan. As a Chinese traditional medicine, 
Huang qin usually refers to the dried root of Scutellaria baicalensis Georgi. Modern 
pharmacokinetic studies have confirmed that baicalein (5, 6, 7-trihydroxyflavone) is a major 
bioactive flavone constituent of Scutellaria baicalensis Georgi (Liu et al., 2017). Baicalein has 
been well known for its broad pharmacological activities, including antibacterial, antiviral, 
anticarcinogenic and anti-inflammatory activities in TCM (Dinda et al., 2017; Huang et al., 2005; Ji 
et al., 2015; Li et al., 2011). Baicalein has a wide safety margin and appears to be able to 
permeate the blood-brain barrier (BBB)(Chen et al., 2016; Liu et al., 2010; Tsai et al., 2002). 
Several in vitro studies have shown that baicalein is effective in preventing neurotoxicity induced 
by a variety of neurotoxins and stress inducers, including Aβ (Lin et al., 2017; Wang et al., 2004), 
6-hydroxydopamine (6-OHDA) (Lee et al., 2005), rotenone (Li et al., 2012),H2O2(Zhang et al., 
2010), and glutamate (Lee et al., 2003), and others. In recent studies, moreover, baicalein has 
been shown to possess neuroprotective properties in several animal models of AD and PD (Cheng 
et al., 2008; Gao et al., 2015; Gu et al., 2016; Zhou et al., 2016). Thus, baicalein has been in the 
focus of research as a versatile therapeutic agent for central neurodegenerative diseases (Fig. 
1)(Gasiorowski et al., 2011). In the following paragraphs, we review the pharmacological actions 
of baicalein in the treatment of AD and PD, and highlight the potential underlying biochemical 
mechanisms of action.  
 
Antioxidant properties of baicalein 
Reactive oxygen species (ROS) are particularly active in the brain as the excitatory amino acids 
neurotransmitters (glutamate) and catecholamine neurotransmitters (dopamine), whose 
metabolism is a source of free radicals, can enhance oxidative stress (Miyazaki and Asanuma, 
2009). Neural cells are considered to be more susceptible to oxidative damage as compared to 
other body tissues, because of limited antioxidant systems in place, higher level of iron in certain 
regions, and high level of unsaturated fatty acids which are more susceptible to peroxidation 
(Uttara et al., 2009).  
 
A large body of evidence has suggested that higher level of markers of oxidative stress including 
protein nitrotyrosine, carbonyls in proteins, lipid oxidation products and oxidized DNA bases exist 
in the brains of AD (Aslan and Ozben, 2004; Korolainen et al., 2006) and PD patients (Sanders and 
Greenamyre, 2013). It is well known that oxidative stress is involved in the pathogenesis of 
neurodegenerative disorders (Khan et al., 2016). In the pathological process, ROS attack neurons 
and glial cells, contributing to DNA injury, proteins misfolding and aggregation, inflammation, 
tissue damage and subsequent cellular apoptosis, which are directly or indirectly linked to 
neuronal cell death. Contrary, antioxidants, including vitamin C, vitamin E, glutathione, coenzyme 
Q (CoQ), carotenoids, and melatonin, have been suggested to prevent or reduce the rate of 
progression of these diseases (Li et al., 2013a). A combination of neurotransmitter supplements 
and antioxidants has been recommended in the treatment of AD or PD. Therefore, development 
of antioxidants as neuroprotective drugs is a potentially beneficial strategy for clinical therapy. 
 
Recently, baicalein has been shown to have beneficial protective effect on the oxidative 
stress-related injury in several in vitro studies. In PC12 cells, baicalein inhibited H2O2-induced cell 
viability loss, intracellular ROS generation, and lipid peroxidation in a dose-dependent manner 
(Zhang et al., 2010). In rotenone-damaged PC12 cells, similarly, baicalein also inhibited the 
accumulation of ROS, ATP deficiency, and mitochondrial membrane potential dissipation (Li et al., 
2012). Baicalein potently reduced Aβ-induced neurotoxicity in PC12 cells, possibly by a reduction 
of oxidative stress (Heo et al., 2004). Moreover, baicalein protected rat cortical neurons from 
Aβ-induced toxicity by its inhibition of oxidative stress. In addition, baicalein effectively protected 
SH-SY5Y cells, a dopaminergic neuroblastoma cell line, from 6-OHDA-induced damage by the 
attenuation of ROS and mitochondrial dysfunction (Lee et al., 2005). Baicalein can protect 
mitochondrial membranes against oxidative damage induced by the four different agents 
(gamma-radiation, peroxyl radicals, ascorbate-Fe2+ and peroxynitrite) (Adhikari et al., 2011). 
Therefore, these findings suggested that baicalein exerts an anti-oxidant effect, which may be 
beneficial for treatment of oxidative stress-related neurodegenerative diseases.  
 
Mechanism of antioxidant stress of baicalein 
Scavenging free radicals  
During oxidative stress, free radicals are directly or indirectly linked to the induced neuronal cell 
death. Free radical scavengers also are beneficial for reducing or preventing progression of 
neurodegenerative diseases (Li et al., 2013a). It is generally accepted that baicalein exerts an 
anti-oxidant effect mainly mediated by scavenging primary and secondary free radicals, including 
superoxide, H2O2, and hydroxyl radicals, during oxidative stress (Hamada et al., 1993). Baicalein 
belongs to the groups of flavonoids. In general, flavonoids contain multiple hydroxyl substitutions 
that exhibit radical scavenging activity. Baicalein has the 5,6,7-trihydroxy structure on ring-A. The 
reported antioxidant properties of baicalein are attributed to these structural features. In 
contrast, baicalin, a glycosylation product of baicalein, has less anti-oxidative activity compared 
with baicalein (Gao et al., 1999; Wozniak et al., 2015). In addition, it has been shown that the 
suppressive effect of baicalein on hydrogen peroxide-induced injury in SH-SY5Y cells was greater 
than that of baicalin (Gao et al., 2001). These finding suggest that antioxidant properties of 
baicalein is primarily dependent on the 5,6,7-trihydroxy structure on ring-A.  
 
Recovering or upregulating antioxidant enzymes   
In general, there is significant endogenous antioxidant depletion in the brain of PD and AD, which 
may aggravate oxidative stress (Mazzetti et al., 2015). Activation of endogenous antioxidants, 
including catalase, superoxide dismutase, and glutathione reductase enzymes, which reduce the 
cellular concentration of free radicals, is a common therapeutic strategy against 
neurodegeneration (Chan and Chan, 2015).  
 
Interestingly, aside from scavenging free radicals, baicalein is able to increase antioxidant 
capabilities by recovering activities of endogenous antioxidant enzymes and upregulating their 
gene expression. Some studies have indicated that formation of dopamine (DA) quinone, a 
DAergic neuron-specific oxidative stressor, plays an important role in the pathogenesis of PD 
(Asanuma et al., 2004; Asanuma et al., 2003; Miyazaki and Asanuma, 2009). However, baicalein 
can prevent the formation of DA semiquinone radicals from DA as shown in an in vitro cell-free 
system. Furthermore, baicalein has neuroprotective properties against excess L-DOPA-induced DA 
neurotoxicity through the suppression of DA quinone formation. Furthermore, the long-term 
treatment of baicalein upregulates the intracellular glutathione (GSH) contents (Takeshima et al., 
2011). One of the mechanisms that neuronal cells have adapted to protect themselves against 
oxidative stress and other insults is the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway 
and the binding of this master transcriptional regulator with antioxidant response element (ARE) 
in the regulatory region of many genes, which leads to the expression of several enzymes with 
antioxidant and detoxification capacities. Notably, manganese superoxide dismutase (MnSOD) is 
an important antioxidant enzyme in mitochondria against oxidative stress. It was found that 
baicalein restored both MnSOD protein expression and its activity, and furthermore restored 
nuclear Nrf2 protein expression and its ARE binding activity (Lee et al., 2011). In addition, 
baicalein protects C6 glial cells against hydrogen peroxide-induced oxidative stress and apoptosis 
through regulation of the Nrf2 signaling pathway (Choi et al., 2016). Hence, these studies 
demonstrate that baicalein attenuates mitochondrial oxidative stress by activating Nrf2-mediated 
MnSOD induction. It can be predicted that the Nrf2 signaling pathway can also be upregulated by 
baicalein in neurons, but further research is needed to confirm this.   
 
Inhibiting lipoxygenase  
It is generally believed that oxidative stress-related genes such as the lipoxygenase (LOX) by 
oxidizing polyunsaturated fatty acids synthesize hydroperoxyacids, which are potent pro-oxidant 
mediators. Especially 12/15-lipoxygenase (12/15-LOX, encoded by the ALOX15 gene), the 
dominant isoform in the brain, is known for its ability to damage mitochondria (Joshi et al., 2015). 
It was found that 12/15-LOX contributes to brain damage after middle cerebral artery occlusion 
(van Leyen et al., 2006). Importantly, the amount of 12/15--LOX is increased in affected frontal 
and temporal regions of AD brains (Pratico et al., 2004), and cerebrospinal fluid levels of both of 
its metabolic products, 12-HETE and 15-HETE, are elevated in individuals with a clinical diagnosis 
of AD (Yao et al., 2005). Moreover, overexpression of 12/15--LOX leads to increased levels of Aβ 
and deposition, phosphorylated tau at Ser 202/Thr 205 and Ser 396 and a worsening of memory 
deficits in AD transgenic mice (Chu et al., 2012; Giannopoulos et al., 2013). On the contrary, 
pharmacologic block and genetic deletion of 12/15--LOX in various AD models improves synaptic 
integrity, and ameliorates Aβ and tau neuropathology, and cognitive impairments (Chu et al., 2015; 
Yang et al., 2010). Therefore, the 12/15--LOX is showing promise as an emerging therapeutic 
target for AD (Joshi et al., 2015).  
 
Besides 12/15—LOX, 5-LOX, another lipoxygenase that is expressed in the CNS, may be involved 
in the process of oxidative stress of PD. 5-LOX was found to be over-expressed in the nigrostriatal 
system after the injection of MPTP into C57BL6 mice. 5-LOX is also involved in rotenone-induced 
damage in PC-12 cells (Zhang et al., 2011). It has also been shown that the over-activation of the 
5-LOX pathway may lead to neurodegeneration by causing lipid peroxidation. In contrast, 
inhibitors of 5-LOX showed neuroprotective effects on (MPTP)/MPP(+)-induced dopaminergic 
neuronal death in midbrain neuron-glia co-cultures and in vivo in mice (Kang et al., 2013). 
Similarly, the 5-LOX inhibitor phenidone attenuated LPS-induced oxidative stress and 
dopaminergic neurodegeneration (Li et al., 2008). In addition, the 5-LOX inhibitor zileuton can 
reduce rotenone-induced cell injury (Zhang et al., 2011).   
 
Recent studies showed that the anti-oxidant effect of baicalein may be mediated by inhibiting 
these oxidative stress-related genes. Baicalein has been regarded as the 12/15-LOX inhibitor and 
has the potential to inhibit the 12/15-LOX pathway (Deschamps et al., 2006; Sadik et al., 2003; 
Sekiya and Okuda, 1982). Furthermore, long-term oral administration of baicalein inhibits 
12/15--LOX enzymatic activity in APP/PS1 mice (Gu et al., 2016). It has been hypothesized that 
the mechanism of baicalein inhibition of 12/15-LOX is by reducing target molecules such as iron, 
which molecular modeling suggests is through direct binding of the catecholic moiety of baicalein 
to the iron. Though there is no information on whether baicalein can inhibit 5-LOX enzymatic 
activity, baicalein reduces oxidative stress in rotenone or 6-OHDA -induced PD cellular models 
(Lee et al., 2005; Li et al., 2012). According to bioactivity and structural characteristics of baicalein, 
it is speculated that baicalein has an inhibitory effect on 5-LOX. However, this requires further 
research to confirm this.  
   
Chelating excessive iron  
Brain iron accumulation in the specific brain regions affected by the disease is a common 
pathological feature of neurodegenerative diseases including AD and PD (Raven et al., 2013). 
Mutations or dysregulation of several proteins related to iron transport leads to abnormal brain 
iron accumulation and have been linked to pathogenesis of AD and PD (Schneider, 2016). The 
elevated iron levels observed in dopaminergic neurons of the substantia nigra of PD subjects 
have been suggested to incite intracellular α-synuclein aggregation (Song et al., 2007; Weinreb et 
al., 2013). Multiple forms of iron accumulation in the brain also demonstrated tau or Aβ 
pathology, suggesting parallels with AD (Kruer, 2013). The most likely mechanism by which Aβ or 
α-synuclein (α-Syn) aggregation may increase oxidative stress in vitro refers to its ability to bind 
iron. Like most transition metals, an excess of intracellular iron is toxic. Through the Fenton 
reaction, iron can react with endogenous hydrogen peroxide to produce the short-lived and 
highly reactive hydroxyl radical (OH·), and further lipid peroxidation and oxidative stress related 
cell death. Recently, the iron-dependent cell death pathway was defined as ferroptosis, which 
was characterized in neurotoxin-induced animal and cellular models of AD or PD (Guiney et al., 
2017; Hambright et al., 2017). Therefore, ferroptosis may also be an important 
neurodegenerative mechanism in diseases such as AD and PD. In neurodegenerative diseases, 
iron chelators may be strong drug candidates to pharmacologically modulate the ferroptotic 
signaling cascade (Do Van et al., 2016; Dusek et al., 2016). 
 
Experiments have shown that baicalein can chelate iron and inhibit iron-induced lipid 
peroxidation and oxidative stress damage. As early as the 1980s, baicalein was observed to 
inhibit iron-induced lipid peroxidation in rat liver (Kimuya et al., 1981). In addition, baicalein has 
also been shown to strongly inhibit iron-dependent lipid peroxidation in microsomes and 
mitochondria (Gao et al., 1995; Gao et al., 1998). Baicalein can protect neurons from 
FeCl3-induced epilepsy (Hamada et al., 1993) and can control iron overload and reduce iron 
overload-induced liver damage in mouse models (Zhang et al., 2006; Zhao et al., 2005). Moreover, 
baicalein prevented ROS-mediated damage of human dermal fibroblast cells better than the iron 
chelator deferoxamine (Gao et al., 1998). The most effective iron binding site of flavonoids is the 
6,7-dihydroxy structure. This site is incorporated in the baicalein molecule and forms, similarly to 
deferoxamine, complexes with iron in the stoichiometry 1:1 and was superior to deferoxamine 
(Mladenka et al., 2011). Baicalein appears to bind the ferrous ion more strongly than ferrozine, a 
well-known iron(II) chelator. Using 1H nuclear magnetic resonance (NMR) and Zn2+ and Ga3+ as 
probes, the iron-binding site on baicalein was elucidated to be at the O6/O7 oxygen atoms of the 
A-ring. No binding was observed for baicalin under the same NMR conditions. Furthermore, 
baicalein strongly inhibits the Fe-promoted Fenton chemistry via a combination of chelation and 
radical scavenging mechanisms while baicalin can provide only partial protection against radical 
damage. These results indicate that baicalein is a strong iron chelator under physiological 
conditions (Perez et al., 2009). In addition, in a natural product library screening for ferroptosis 
inhibitors, it was found that baicalein is a potent inhibitor of erastin-induced ferroptosis in 
pancreatic cancer cells (Xie et al., 2016). Baicalein exhibits remarkable anti-ferroptosis activity 
compared with well-known ferroptosis inhibitors such as ferrostatin-1, liproxstatin-1, 
deferoxamine mesylate, and β-mercaptoethanol(Xie et al., 2016). Thus, based on these findings, 
baicalein may have the potential to treat neurodegenerative diseases by chelating excessive iron.  
 
In conclusion, these above findings suggest that baicalein has antioxidant stress effects by 
scavenging free radicals, upregulating antioxidant enzymes, inhibiting lipoxygenase, and chelating 
excessive iron. Hence, baicalein may be an effective antioxidant stress agent for 
neurodegenerative diseases.  
 
Baicalein inhibits aggregation of disease-specific amyloid proteins    
Neurodegenerative diseases share a similarity in aggregation of disease-specific amyloid proteins 
in the brain. Amyloids are β-sheet rich fibrillar aggregates formed by self-assembly of different 
proteins including Aβ and α-Syn. Accumulation of abnormally folded Aβ plaque occurs in the 
brain of AD patients, and abnormally folded α-Syn is the major component of Lewy bodies, which 
are intracellular inclusions present in the dopaminergic neurons of PD patients’ brains (Spillantini 
et al., 1997). Mutations of β-amyloid precursor protein (APP) or α-Syn are linked with familial 
early-onset AD or PD (Goedert, 2015). Thus, these disease-specific amyloid proteins (Aβ and 
α-Syn) are considered to be the key molecule to be targeted for AD or PD therapy. It has been 
suggested that the precursors of fibrils, oligomeric α-Syn or Aβ, might be more toxic than mature 
fibrils, are mediating α-Syn and Aβ neurotoxicity (Glabe and Kayed, 2006; Kayed et al., 2003; 
Volles and Lansbury, 2003). Though the molecular mechanisms underlying amyloid proteins 
aggregation remain unknown, compounds that can slow and/or prevent the fibrillation and 
aggregation process of α-Syn or Aβ, could lead to a new therapeutic strategy for treating PD and 
AD.       
    
Interestingly, studies have shown that baicalein can inhibit the aggregation of disease-specific 
amyloid proteins. Low micromolar concentrations of baicalein, and especially its oxidized forms, 
inhibit the formation of α-Syn fibrils. In addition, existing fibrils of α-Syn are disaggregated by 
baicalein (Zhu et al., 2004). Subsequent biophysical studies and in vitro/vivo studies 
demonstrated that baicalein is capable of mitigating α-Syn aggregation and reducing cytotoxicity 
(Caruana et al., 2012; Hu et al., 2016; Jiang et al., 2010; Lu et al., 2011). Baicalein is a potent 
inhibitor of α-Syn oligomerisation both in cell-free and cellular systems, and is also an effective 
inhibitor of α-Syn fibrillation in cell-free systems. Baicalein inhibited the formation of α-Syn 
oligomers in SH-SY5Y and Hela cells, and protected SH-SY5Y cells from α-Syn -oligomer-induced 
toxicity (Lu et al., 2011). Besides inhibition of wild-type α-Syn aggregation and cytotoxicity, 
several researchers found that baicalein also reduced mutant (A30P, A53T and E46K) α-Syn 
aggregation in vitro and plays a protective role in N2A cell models of familiar Parkinsonism 
(Caruana et al., 2012; Jiang et al., 2010). Moreover, Baicalein attenuated α-Syn aggregation in the 
MPP+-treated nigrostriatal dopaminergic system of the rat brain (Hung et al., 2016). In a chronic 
PD mouse model created by continuous intragastric administration of rotenone, baicalein did not 
decrease α-Syn mRNA expression, but α-Syn oligomers were significantly decreased in the ileum, 
thoracic spinal cord, and midbrain. Taken together, these results suggest that baicalein could 
prevent the progression of α-Syn accumulation in PD partly by inhibiting formation and 
aggregation of the α-Syn oligomers (Hu et al., 2016).  
 
In addition, baicalein can also inhibit Aβ fibrillation and oligomerisation, disaggregate pre-formed 
Aβ amyloid fibrils and prevent Aβ fibril-induced toxicity in PC12 cells(Lu et al., 2011). In cell 
cultures, baicalein significantly reduced the production of Aβ by increasing APP α-secretase 
processing. AD transgenic mice treated daily with baicalein for 8 weeks showed enhanced APP 
α-secretase processing and reduced Aβ production (Zhang et al., 2013).      
  
Though the exact molecular mechanism of inhibition of aggregation of amyloid proteins of 
baicalein is not clear, the underlying mechanism was thoroughly examined by various 
biochemical and biophysical approaches, and a mechanism based on special molecular structure 
characteristic of baicalein has been proposed. In fact, it has long been known that polyphenols, 
such as baicalein and other flavonoids, are reductive substances that are readily oxidized to 
quinones by oxygen, while quinones are very reactive and can react with the side-chain amino 
groups of proteins. Oxidized forms of baicalein, baicalein quinones, play a critical role in the 
inhibition reaction, and the product of the inhibition reaction is predominantly a soluble 
oligomer of α-Syn, in which the protein molecules have been covalently modified by baicalein 
quinone to form a Schiff base with a lysine side chain in α-Syn, and Tyr is involved in the 
interaction of α-Syn with baicalein (Zhu et al., 2004). Further structure-activity analysis showed 
that vicinal dihydroxyphenyl moieties of baicalein are required for quinone formation and 
attachment to α-Syn, and baicalein with three vicinal hydroxyl groups exhibited the enhanced 
inhibitory effects on α-Syn fibrillation compared to baicalin with two vicinal hydroxyl groups 
(Caruana et al., 2012). The antioxidant activities of baicalein is correlated with their in vitro 
inhibitory effects on α-Syn fibrillation (Meng et al., 2009). Interestingly, a recent study indicated 
that baicalein-stabilized α-Syn oligomers are able to inhibit fibrillation of non-baicalein-treated 
α-Syn. These highly stable α-Syn oligomers that inhibit fibrillation do not disrupt the integrity of 
the biological membrane, suggesting that some forms of soluble oligomer formation can be 
beneficial (Hong et al., 2008). Therefore, these results suggest that baicalein has potential as a 
therapeutic agent for the treatment of neurodegenerative diseases such as AD, PD and 
tauopathies by inhibition of aggregation of disease-specific amyloid proteins.  
     
Anti-inflammatory properties of baicalein  
A key element of disease progression in neurodegenerative diseases is the development of a 
chronic neuroinflammation response in the brain (Ferrari and Tarelli, 2011; Heneka et al., 2015a). 
Clinical studies observed significant microglial and astrocyte activation in the affected brain 
regions of patients with PD or AD. High concentrations of proinflammatory cytokines such as 
interleukin (IL)-1β, IL-6, and tumor necrosis factor α (TNF-α) have been found in the brain, 
cerebral spinal fluid, and blood of AD and PD patients (Chen et al., 2008). Neuroinflammatory 
processes contribute to the cascade of events culminating in neuronal damage. Elevated 
production of proinflammatory cytokines by activated microglia and astrocyte can lead to 
synapse dysfunction and ultimately synapse loss (Herrero et al., 2015). Moreover, the chronic 
neuroinflammation response is considered to play a role in promoting the formation of 
pathological plaque including senile plaque (Heneka et al., 2015b) and Lewy's body 
(Garcia-Esparcia et al., 2014). Therefore, anti-inflammatory medication always is an effective 
therapeutic or preventive strategy for CNS neurodegenerative diseases (Hirohata et al., 2008). 
   
In oriental countries, the root of Scutellaria baicalensis Georgi has been widely used against 
various inflammatory diseases, and infections of the respiratory and gastrointestinal tract for 
centuries. As the major active component of the herbal medicine, baicalein has also been 
reported to exhibit potent anti-inflammatory effects in several topical and systematic 
inflammatory diseases (Dinda et al., 2017). As early as 1984, baicalein was found to inhibit the 
acetic acid-induced increase in vascular permeability in mice and to reduce acute paw edema in 
the rats (Kubo et al., 1984), and baicalein also suppressed the development of secondary lesions 
in adjuvant-induced arthritis in rats (Kubo et al., 1984). Baicalein also attenuates inflammatory 
responses in LPS-induced mastitis in mice (He et al., 2015). Moreover, a Chinese patent medicine 
of baicalein, the capsule preparation of baicalein aluminum, is approved for treatment of 
enteritis and dysentery in clinic (Wang et al., 2016a).   
 
A growing number of studies have showed that baicalein is capable of inhibiting 
neuroinflammation in the CNS, and anti-inflammation has been proposed as one of the major 
mechanisms underlying baicalein-induced neuroprotection. In primary midbrain neuron-glia 
cultures from E-14 rat embryos, it was found that baicalein exerts potent neuroprotective effect 
on LPS-induced injury of dopaminergic neurons (Li et al., 2005). Baicalein almost completely 
blocked LPS-induced activation of microglia, and the excessive production of TNF-α by LPS 
stimulation was also attenuated by baicalein in a concentration-dependent pattern (Li et al., 
2005). In ischemic brain injury, baicalein exhibits its anti-inflammatory activity by inhibiting the 
infiltration of neutrophil cells (Hwang et al., 2002). Baicalein also exerts a protective effect on 
BBB disruption in the rat model of intracerebral hemorrhage (ICH). Additionally, baicalein 
attenuates astroglial activation and inflammasome activation in the MPTP-induced PD model 
(Cheng et al., 2008; Lee et al., 2014). Moreover, Baicalein alleviates early brain injury after 
experimental subarachnoid hemorrhage in rats by inhibiting inflammatory pathways (Wang et al., 
2015a). Baicalein prevents neuroinflammation and memory impairments in accelerated 
senescense mice (Jeong et al., 2011). In conclusion, these findings show that baicalein has the 
potential to inhibit neuroinflammation through attenuation of glial activation and associated 
cytokine release in CNS neurodegenerative diseases.  
 
Data suggest that the likely mechanism by which baicalein inhibits inflammation is related to the 
inhibition of the nuclear factor-κB (NF-κB) signaling pathways (Chen et al., 2016; Spencer et al., 
2012). NF-κB is a multi-subunit nuclear transcription factor rapidly activating the transcription of 
various cytokines and chemokines. The expression of many inflammation-related genes is 
controlled through the NF-κB signaling pathway (Park and Hong, 2016). Baicalein can inhibit 
NF-κB activation and inhibitor of NF-κB (IκB) degradation, and significantly inhibits the 
phosphorylation of p38, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 
(JNK) activated by LPS-induced mouse mastitis (He et al., 2015). In experimental subarachnoid 
hemorrhage of rats, baicalein also alleviates early brain injury via the TLR4/NF-κB-mediated 
inflammatory pathway (Wang et al., 2015a). In the MPTP-induced PD model, baicalein attenuates 
astroglial activation by downregulating the activations of NF-κB, ERK, and JNK (Lee et al., 2014).   
 
Besides inhibition of NF-κB signaling pathways, baicalein may have the potential to inhibit 
neuroinflammation through the attenuation of iNOS expression and nitric oxide (NO) production. 
It was shown that baicalein inhibits LPS-induced NO production in a concentration-dependent 
manner in RAW 264.7 macrophages, which was in parallel with the inhibition of iNOS gene 
expression (Chen et al., 2001). Moreover, baicalein also inhibited iNOS expression in microglia (Li 
et al., 2005). Accumulating evidence indicated that iNOS was the most important contributor to 
NO production in the brain after inflammatory assault, compared with the other isoforms of NOS, 
i.e., eNOS and nNOS (Iravani et al., 2002). Excessive accumulation of NO has long been known to 
be toxic to neurons (Steinert et al., 2010). When NO meets with superoxide, peroxynitrite is 
formed, that is a potent oxidant and nitrating agent capable of attacking and modifying proteins, 
lipids and DNA as well as depleting antioxidant defenses(Radi, 2013). Some authors think that the 
powerful neuroprotective effect of baicalein is derived from its dual functions in inhibiting both 
superoxide and NO production and consequent formation of lethal peroxynitrite (Li et al., 2005). 
In addition, baicalein may be anti-inflammatory by interacting Nrf2 to regulate the redox balance 
(Choi et al., 2016) (Lee et al., 2011).  
 
In summary, a significant body of studies has focused on the anti-inflammatory mechanisms 
underlying baicalein-induced neuroprotection. Therefore, baicalein’s anti-inflammatory 
properties add to its value as a therapy for neurodegenerative diseases.   
  
Baicalein inhibits excitotoxicity 
Excitotoxicity induces neuronal degeneration, triggered by the over- or prolonged activation of 
glutamate receptors in the CNS by excitatory amino acids. Glutamate is a major excitatory 
neurotransmitter and plays an important role in the mammalian CNS. However, excess glutamate 
is highly toxic to neurons (Lewerenz and Maher, 2015). Substantial experimental and clinical 
studies show that glutamate excitotoxicity pathway may play a substantial role in the 
pathogenesis of neuronal death in central neurodegenerative diseases such as AD (Esposito et al., 
2013; Tannenberg et al., 2004) and PD (Blandini et al., 2001). The clinical use of the 
noncompetitive N-methyl-d-aspartate (NMDA) antagonist memantine in monotherapy or 
combination therapy with cholinesterase inhibitors improved cognition, behavior, and activities 
of daily living of AD patients (Matsunaga et al., 2015; Owen, 2016) and PD dementia patients 
(Olivares et al., 2012; Wang et al., 2015b). Therefore, inhibition of glutamate release or 
antagonism of glutamate receptors is a potentially valuable therapeutic strategy for treating 
these diseases.  
 
Recently, some authors demonstrated that baicalein can inhibit excitotoxicity in several animal 
models of neurodegeneration. It was found that baicalein can protect neurons from a variety of 
stresses, including those exerted by glutamate (Lee et al., 2003). Baicalein also attenuates 
methamphetamine-induced loss of dopamine transporter in mouse striatum (Wu et al., 2006). In 
the PD rat model induced by 6-OHDA-medial forebrain bundle (MFB) injection, baicalein plays a 
neuromodulatory role in balancing gamma aminobutyric acid (GABA) and glutamate 
neurotransmitter levels in the basal ganglia (Yu et al., 2012). In rat primary mesencephalic 
cultures, baicalein inhibited the glutamate -induced intracellular calcium ion increase. Baicalein 
also showed neuroprotective effects on excitotoxic neuronal cell death in primary rat cortical cell 
cultures (Yang et al., 2014). Interestingly, an improved drugs screening system revealed that 
baicalein not only ameliorates the Aβ-induced depolarization of neurons, but also possibly 
functions as an antagonist of AMPA and NMDA receptors (Lin et al., 2017). In rat hippocampal 
nerve terminals (synaptosomes), baicalein inhibits depolarization-induced glutamate release, 
while in slice preparations whole cell patch-clamp experiments revealed that baicalein reduced 
the frequency of miniature excitatory postsynaptic currents without affecting their amplitude. 
Further studies showed that inhibiting excitotoxicity of baicalein was mediated through the 
inhibition of NMDA receptor function by interacting with the glycine binding site of the NMDA 
receptor. In animal models of neurodegeneration, excitotoxicity is commonly induced 
experimentally by kainic acid (Mohd Sairazi et al., 2015). In a kainic acid rat model, 
intraperitoneally administering baicalein substantially attenuated kainic acid-induced neuronal 
cell death, c-Fos expression, and the activation of the mammalian target of rapamycin in the 
hippocampus (Chang et al., 2016). Therefore, these findings suggest that baicalein is valuable for 
treating brain disorders related to glutamate excitotoxicity.    
 
Neurogenesis and cell differentiation action of baicalein   
Neuronal loss in the disease-specific brain regions following neurotransmitter decrease and 
synapse loss are the main cause of the typical cognitive and motor symptoms of 
neurodegenerative diseases. In AD, the basal forebrain, the hippocampus and its neighboring 
cortical structures within the temporal lobe lose a large number of cholinergic neurons, and 
acetylcholine neurotransmission is lost, which impairs the cognitive ability of AD patients 
(Lombardo and Maskos, 2015). In PD, there is loss of dopaminergic neurons in the substantia 
nigra, and loss of dopaminergic projections to the basal ganglia, which declines motor ability of 
PD patients (Gaig and Tolosa, 2009). It is now widely accepted that lack of endogenous 
neurotrophic factors, such as glial cell line-derived neurotrophic factor (GDNF), nerve growth 
factor (NGF) and brain-derived neurotrophic factor (BDNF), is involved in several 
neurodegenerative diseases (Allen et al., 2013; Holscher, 2014; Lee and Son, 2009). Therefore, 
any therapeutics that can promote neurotrophic and neurogenesis to remedy neuronal loss will 
be a promising therapeutic strategy for neurodegenerative diseases.  
 
Recently, both neurotrophic and neurogenesis action of baicalein has been verified in a series of 
studies, in which the molecular mechanisms of the neurogenetic effect of baicalein have been 
studied. Baicalein can attenuate the irradiation-induced impairment of hippocampal 
neurogenesis by modulating oxidative stress and elevating BDNF-pCREB signaling (Oh et al., 
2013). Moreover, baicalein might also promote neurogenesis in MPTP-treated mice by 
up-regulation of a series of genes such as SRY (sex-determining region Y)-box 8 (SOX8) and SRY 
(sex-determining region Y)-box 11 (SOX11), genes that can promote endogenous neurogenesis 
(Gao et al., 2015). In addition, baicalein enhanced the survival of HiB5, a hippocampal progenitor 
cell line, and its differentiation to ChAT immunoreactive cells (Heo et al., 2009). Baicalein also 
induced cortical neurogenesis after focal cerebral ischemia, and baicalein treatment was found to 
promote differentiation of cortical precursor cells into neuronal but not glial cells, which may be 
attributable to the regulation of AKT, GSK-3β mRNA and Ang-1 protein levels (Zou et al., 2016). 
Therefore, these findings suggest that baicalein most likely acts as a neurotrophic and 
neurogenetic drug that may be useful for treating neurodegenerative diseases. 
   
Anti-apoptotic effects of baicalein 
During development and maturation of the CNS, neuronal apoptosis is a physiological process 
that is an integral part of neurogenesis. However, aberrant apoptosis has been implicated in the 
pathogenesis of neurodegeneration (Okouchi et al., 2007). Evidence of increased neuronal 
apoptosis, such as DNA damage, apoptotic bodies, chromatin condensation, and the induction of 
select genes that take part in apoptosis including bax and caspases, have been observed in 
affected brain regions (the hippocampus or the substantia nigra) of the AD or PD brain (Rohn and 
Head, 2009; Schulz, 2006). These neuropathological processes were found in cell culture and 
animal models of neurodegeneration induced by neurotoxins (Bove and Perier, 2012; Cotman 
and Su, 1996). Based on the available data in animal models and studies involving postmortem 
patients, therefore, several potential candidates of the apoptotic machinery have been 
uncovered as possible drug targets for the treatment of AD or PD (Rohn and Head, 2009). 
  
Several studies in cellular and animal models have shown that baicalein may have anti-apoptotic 
effects in neurons. Baicalein can block 6-OHDA-induced SH-SY5Y cell apoptosis (Mu et al., 2009). 
Furthermore, the mitochondrial pathway associated with cell apoptosis including membrane 
potential loss, the release of cytochrome c, the downregulation of Bcl-2, upregulation of Bax 
induced by H2O2 was also abrogated in the presence of baicalein (Zhang et al., 2010). Moreover, 
baicalein suppressed rotenone-induced PC12 cells apoptosis, and inhibited the accumulation of 
ROS, ATP deficiency, mitochondrial membrane potential dissipation, and caspase-3/7 activation in 
a concentration-dependent manner (Li et al., 2012). In addition, baicalein inhibited 
MPP+-induced apoptosis and the activation of caspases 9 and 12 in the rat nigrostriatal 
dopaminergic system (Hung et al., 2016). Baicalin effectively prevented Aβ-induced mitochondrial 
membrane potential decrease, Bax/Bcl-2 ratio increase, cytochrome c release, and caspase-9/-3 
activation. In primary cultured cortical neurons stressed by oxygen and glucose deprivation, 
similarly, baicalein increased Bcl-2/Bcl-xL-associated protein phosphorylation and maintained the 
protein levels of Bcl-2 in mitochondria, which subsequently reduced cytochrome c release into 
the cytosol (Liu et al., 2010). Baicalein protected HT22 murine hippocampal neuronal cells against 
endoplasmic reticulum stress-induced apoptosis via inhibition of ROS production and CHOP 
induction (Choi et al., 2010). Furthermore, baicalein also markedly reduced apoptosis in the 
penumbra of transient middle cerebral artery occlusion rats (Liu et al., 2010). These results 
showed that baicalein-induced attenuation of neurotoxins -induced apoptosis is mediated via 
inhibiting mitochondrial and ER stress pathways. Thus, baicalein may be a beneficial 
neuroprotective drug by inhibiting neuronal apoptosis.   
 
Clinical trials of baicalein  
Baicalein has potential as a novel neuroprotective agent for the treatment of neurodegenerative 
diseases. Hence, clinical trials of baicalein for treating neurodegenerative diseases are necessary. 
Notably, two Phase I clinical trials of baicalein chewable tablets in healthy Chinese adult 
volunteers have been completed in China.  
 
In 2014, a Phase I, randomized, double-blind, single-dose trial of baicalein (100-2800 mg) in 72 
healthy Chinese adults investigated the pharmacokinetic (PK) properties of baicalein and its main 
metabolite, bacalin. Samples of blood, urine and feces were collected at regular intervals up to 48 
h after administration of the drug. The drug concentration was then analyzed using liquid 
chromatography-tandem mass spectrometry (LC/MS/MS). Physical examinations, vital signs, ECG 
findings, hematology, and urinalysis were monitored before and at regular intervals after 
administration of the drug. The PK profile of baicelein and baicelin was characterized by a median 
Tmax of 0.75-3.5 h and 0.5-3 h, respectively, followed by a multiphasic profile with a t₁/₂ of 
1.90-15.01 h and 4.22-10.80 h, respectively. The estimates of the proportionality coefficient (90% 
CI) for Cmax, AUC₀-t and AUC₀-∞ were 0.83 (0.70-0.96), 0.91 (0.81-1.00) and 0.92 (0.82-1.02), 
respectively. All values overlapped within the pre-specified range of (0.89-1.11), (0.93-1.07), and 
(0.93-1.07), respectively. The total urinary clearance of baicalein and baicalin was <1%. And 
approximately 27% of baicalein was eliminated as unchanged drug in feces. Moreover, baicalein 
was well tolerated. Eleven treatment-related adverse events (hyperactive bowel sounds, 
abdominal distention, constipation, dizziness, somnolence, blurred vision, plasma fibrinogen 
decreased, blood leukocyte decreased, etc.) were observed in the higher dose group, and all 
were rated as "mild" and resolved without further treatment. There were no clinically relevant 
changes in blood pressure or ECG in individuals during the study. No serious adverse events 
occurred, and clinical laboratory assessments showed no signs of toxicity in the liver or kidney. (Li 
et al., 2014)  
 
In 2016, another single-center, double-blind, placebo-controlled, parallel-group study 
investigated the PK, safety and tolerability of baicalein after a multiple-ascending-dose protocol 
in healthy Chinese volunteers. In this clinical trial, participants were randomized to receive 
baicalein (n = 8 per dose regimen) or placebo (n = 2 per dose regimen). Dosing regimens were 
200, 400, and 800 mg once daily on days 1 and 10, twice daily on days 3-9. Plasma, urine, and 
feces samples were assayed for baicalein and its predominant metabolite baicalin using validated 
HPLC-MS/MS methods. Thirty-three of 36 enrolled participants completed the study. A total of 44 
adverse events occurred in 23 participants. A steady-state concentration of analytes in plasma 
was achieved on day 8 after repeated dosing. Analytes concentrations and exposure increased 
with increasing dose. The dose proportionality constant (β) for AUCss of baicalein and baicalin 
was 0.922 (90 % confidence interval, 0.650-1.195) and 0.942 (90 % confidence interval, 
0.539-1.345), respectively. The accumulation index varied from 1.66 to 2.07 for baicalein and 
from 1.68 to 2.45 for baicalin. In conclusion, in dose range of 200-800 mg, multiple-dose oral 
baicalein administration was safe and well tolerated, dose proportionality was inconclusive, and 
no serious accumulation of baicalein was observed (Pang et al., 2016). 
 
Although two Phase I clinical trials have indicated that oral baicalein is safe and well tolerated, , 
clinical trials for other dosages for baicalein are not reported, and further phase II and III clinical 
trials of baicalein in AD and PD patients will have to be conducted to prove its efficency. 
 
Conclusion 
The neuroprotective effects of baicalein in AD and PD have been widely investigated in in 
vitro/vivo studies. To summarize, balcalein shows antioxidant effects, has anti-inflammatory 
properties, inhibits the aggregation of disease-specific amyloid proteins, reduces excitotoxicity, 
enhances neurogenesis and cell differentiation, and has anti-apoptotic effects. This forms a solid 
base to propose baicalein as a treatment for neurodegenerative diseases (Fig. 1). Importantly, 
two phase I clinical trials of baicalein in healthy Chinese adult volunteers have been completed (Li 
et al., 2014; Pang et al., 2016) and confirmed that baicalein is safe and well tolerated by healthy 
subjects. Thus, all of these properties indicate that the therapeutic implications of baicalein may 
prove successful in slowing or even halting further progression of CNS neurodegenerative 
diseases. Baicalein has the potential to be used alone or in combination with existing drugs for 
AD and PD patients. As the next step, clinical trials testing the effects in patients with 
neurodegenerative disorders will have to be initiated to test what the actual benefits will be. 
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Fig. 1：The pharmacological effects of baicalein on neurodegenerative diseases  
In Chinese traditional medicine, Huang qin usually refers to the dried root of Scutellaria 
baicalensis Georgi. Baicalin is a major hydrosoluble constituent in the decoction of Huang qin. 
After entering the human body, baicalin is hydrolyzed into baicalein by β-D-glucosidases, and 
baicalein can cross the BBB into the brain. Baicalein has antioxidant effects in the CNS by 
scavenging free radicals, by upregulating antioxidant enzymes, inhibiting lipoxygenase, and 
chelating excessive iron. Baicalein, especially baicalein quinone (its oxidized forms), might inhibit 
aggregation of disease-specific amyloid proteins (Aβ and α-Syn) by formation of a Schiff base with 
Aβ or α-Syn. The vicinal dihydroxyphenyl moieties of baicalein are required for quinone formation 
and attachment to amyloid proteins. Baicalein can reduce the chronic neuroinflammation 
response and production of proinflammatory cytokines by inhibiting the expression of iNOS and 
the production of NO, as well as by the inhibition of the NF-κB signaling pathways in glial cells. 
Baicalein may inhibit excitotoxicity by reducing glutamate release and antagonizing NMDA 
receptor. Baicalein may promote neurogenesis and neural cells differentiation by upregulating 
BDNF signaling pathway. Baicalein also has anti-apoptotic effects by inhibiting mitochondrial and 
ER stress signaling pathways. Based on these multiple pharmacological effects, baicalein shows a 
therapeutic potential for treating AD and PD.   
 
 
 
